Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Our mission is to develop transformative therapies to treat rare and underserved eye diseases

See How

Innovation in Eye Therapeutics

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

  • OCU300
    For ocular graft versus host disease (oGVHD)
  • OCU400
    For treatment of NR2E3 mutation-associated retinal degeneration
  • OCU200
    For wet age-related macular degeneration

Addressing a common complication that occurs in about 60% of patients who have undergone allogeneic hemotological stem cell transplantation, or bone marrow transplants.

Learn More About OCU300

Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.

Learn More About OCU310

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400

Addressing a group of inherited diseases that cause progressive retinal degeneration, affecting approximately 100,000 people in the US and similar number in Europe.

Learn More About OCU100

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

OCU300
For ocular graft versus host disease (oGVHD)

Addressing a common complication that occurs in 40-60% of patients who have undergone allogenic hemotological stem cell transplantation, or bone marrow transplants.

Learn More About OCU300

OCU400
For treatment of NR2E3 mutation-associated retinal degeneration

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400
OCU200
For wet age-related macular degneration

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200

Press Releases

Sign up to receive email alerts with the latest news from Ocugen Subscribe